复方阿嗪米特肠溶片对消化不良患者的疗效和安全性评价

目的:评价复方阿嗪米特肠溶片对消化不良患者的疗效及安全性。方法:选取93例消化不良患者,根据引发消化不良病症的不同病因,给予复方阿嗪米特肠溶片治疗;观察治疗前后患者病症的改善情况。结果:治疗后,患者消化不良的总有效率达84.95%;治疗后患者食欲不振、恶心呕吐、便秘、胃部具灼烧感(胃酸过多)、腹痛、腹胀和嗳气症状积分值优于治疗前(P<0.05);治疗过程中未出现严重药物不良反应。结论:复方阿嗪米特肠溶片对功能性消化不良患者的疗效较显著,能有效缓解其临床症状,且安全性较高。     

复方阿嗪米特肠溶片联合多潘立酮治疗功能性消化不良的疗效观察

目的:探讨复方阿嗪米特肠溶片联合多潘立酮治疗功能性消化不良的临床疗效。方法:选取某院收治的106例功能性消化不良患者,以患者自愿原则为依据将其分为观察组和对照组,每组53例,对照组患者采用单纯多潘立酮治疗,观察组患者则采用复方阿嗪米特肠溶片联合多潘立酮治疗,比较两组患者的治疗总有效率及治疗前后患者症状积分情况。结果:观察组患者治疗总有效率及治疗后嗳气、餐后饱胀、上腹部灼烧感、上腹痛等症状积分比较均有显著统计学意义(P0.05)。结论:给予功能性消化不良患者复方阿嗪米特肠溶片联合多潘立酮治疗可有效的提高治疗效果,改善患者临床症状,具有较高的应用价值,应予推广应用。     

复方阿嗪米特肠溶片与复方消化酶胶囊治疗腹胀的疗效

目的观察国产复方阿嗪米特肠溶片与进口复方消化酶胶囊2种药物对功能性消化不良、慢性胆囊炎、胆结石、肝硬化及慢性胰腺炎引起的腹胀的疗效及安全性。方法138例腹胀病人分为治疗组72例,对照组66例,治疗组给予复方阿嗪米特肠溶片2粒,3次·d~(-1),对照组给予复方消化酶胶囊2粒,3次·d~(-1),均为餐后服,疗程为2 wk。观察治疗前后腹胀症状积分及2组疗效。结果复方阿嗪米特肠溶片同复方消化酶胶囊都能明显改善功能性消化不良、慢性胆囊炎、胆结石、肝硬化及慢性胰腺炎病人的腹胀症状,治疗2 wk腹胀症状积分均明显下降(P<0.01),腹胀总有效率达80%～89%。2组疗效无显著差异(P>0.05),治疗过程中均无不良反应发生。结论复方阿嗪米特肠溶片是治疗功能性消化不良、慢性胆囊炎、胆结石、肝硬化及慢性胰腺炎病人腹胀安全有效的药物。     

枸橼酸莫沙必利片联合复方阿嗪米特肠溶片治疗功能性消化不良200例临床观察

目的观察联用枸橼酸莫沙必利片和复方阿嗪米特肠溶片治疗功能性消化不良的疗效。方法将200例功能性消化不良患者随机分成2组,每组100例。治疗组给予枸橼酸莫沙必利片联合复方阿嗪米特肠溶片治疗;对照组单用枸橼酸莫沙必利片。观察用药2周后和4周后2组的临床症状变化。结果 2周及4周后在腹胀积分变化、腹胀总有效率、食欲不振总有效率三个方面治疗组都优于对照组,2者差异有统计学意义(P<0.05),且在腹胀积分变化观察中治疗组4周疗效优于2周后,2者差异有统计学意义(P<0.05)。结论枸橼酸莫沙必利片联合复方阿嗪米特肠溶片能够有效的缓解功能性消化不良的腹胀、食欲不振的症状,并两者具有一定的协同作用。     

复方阿嗪米特肠溶片联合马来酸曲美布汀治疗功能性消化不良疗效观察

目的观察复方阿嗪米特肠溶片联合马来酸曲美布汀治疗功能性消化不良的的疗效。方法104例功能性消化不良患者采用完全随机设计方法分成2组，观察组54例，给予复方阿嗪米特肠溶片100mg，3次／d，餐后服用；马来酸曲美布汀100mg，3次／d，餐前服用。对照组50例，单用复方阿嗪米特肠溶片100mg，3次／d，餐后服用，疗程均2周。观察治疗前、后，饭后腹胀及腹部不适症状改善情况、食欲改善时间及复诊率。结果2组腹胀症状及改善食欲方面无统计学意义，饭后腹部不适症状观察组较对照组改善明显，并能降低复诊率。治疗过程中2组均无药物不良反应出现。结论复方阿嗪米特肠溶片和马来酸曲美布汀联合应用，治疗消化不良患者疗效明显，药物不良反应少，既安全又有效。     

复方阿嗪米特肠溶片联合多潘立酮治疗功能性消化不良患者的临床疗效研究

目的复方阿嗪米特肠溶片联合多潘立酮治疗功能性消化不良患者的临床疗效。方法 80例功能性消化不良患者随机分为两组,Ⅰ组40人为对照,应用单用多潘立酮治疗;Ⅱ组40人,使用复方阿嗪米特与多潘立酮联合治疗。结果经治疗后,Ⅰ组、Ⅱ组两组治疗方法都有着一定的功效,与治疗前相比,都有着一定的改善,两组相比较来看,Ⅰ组对照临床有效率为67.5%,Ⅱ组临床有效率为90%,Ⅱ组的治疗疗效明显优于对照组Ⅰ组(P<0.05)。结论复方阿嗪米特肠溶片联合多潘立酮治疗功能性消化不良有着较好的医疗效果,不良反应发生率较低,值得在临床上推广研究。     

复方阿嗪米特肠溶片联合枸橼酸莫沙必利分散片治疗小儿功能性消化不良

目的:评价复方阿嗪米特肠溶片联合枸橼酸莫沙必利分散片在治疗小儿功能性消化不良中的临床疗效和安全性.方法:将儿科门诊中被确诊为功能性消化不良的68例患儿随机分成A、B、C 3组,A组口服枸橼酸莫沙必利分散片和复方阿嗪米特肠溶片,B组单口服枸橼酸莫沙必利分散片,C组单口服复方阿嗪米特肠溶片,比较各组的腹胀积分改善情况及食欲不振、恶心、呕吐、腹泻、腹痛、腹胀等6个症状的消失时间.结果:治疗后7、14 d时3组患儿的腹胀积分均显著低于治疗前(P0.01或P0.05);B、C组患儿治疗后7、14 d时腹胀积分改善率显著低于A组(P0.01或P0.05);A组治疗后7、14 d时的腹胀改善总有效率分别达到81.8%、95.5%,均显著高于B、C组(P0.05).B、C组患儿食欲不振、恶心、呕吐、腹泻、腹痛、腹胀等6个症状的消失时间明显长于A组,差异有统计学意义(P0.05).结论:联合使用复方阿嗪米特肠溶片及枸橼酸莫沙必利分散片治疗小儿功能性消化不良起效更快,疗效更佳,尤其是对于腹胀积分较高的惠儿,值得临床推广.     

复方阿嗪米特肠溶片治疗慢性胰腺炎化学性消化不良疗效观察

目的观察复方阿嗪米特肠溶片治疗慢性胰腺炎化学性消化不良的效果。方法76例慢性胰腺炎患者随机分为2组：复方阿嗪米特肠溶片组（治疗组）40例,复方消化酶胶囊组（对照组）36例。均连续用药4周,观察临床症状变化。结果治疗组2周有效率86％,4周总有效率90％,与对照组比较,差异有统计学意义（P〈0．05）。结论复方阿嗪米特肠溶片治疗慢性胰腺炎化学性消化不良疗效较好。     

小儿功能性消化不良104例治疗分析

目的评价莫沙必利联合复方阿嗪米特肠溶片治疗小儿功能性消化不良的临床效果及安全性。方法将104例功能性消化不良患儿随机分成观察组、对照组,观察组52例在常规治疗基础上口服莫沙必利片及复方阿嗪米特肠溶片,对照组52例仅服莫沙必利治疗,分析两组食欲不振、恶心、呕吐、腹泻、腹痛、腹胀等症状的缓解及消失情况。结果两组患儿治疗后的症状均显著缓解（P〈0．01）;观察组患儿食欲不振、呕吐、腹泻、腹痛等症状消失时间明显短于对照组,差异有统计学意义（P〈0．05）;观察组患儿治疗7d后,显效率达到61．5％,明显高于对照组的34．6％（P〈0．05）。结论莫沙必利联合复方阿嗪米特肠溶片治疗小儿功能性消化不良具有疗效佳,起效快等优点。     

复方阿嗪米特肠溶片对功能性消化不良的治疗效果分析

目的：功能性消化不良（Functional dyspepsia,FD）,是一组常见的胃肠道疾病,本文旨在观察分析复方阿嗪米特肠溶片治疗功能性消化不良的疗效。方法：本研究选择了于2014年1～12月在我院就诊的功能性消化不良患者100例,随机分为观察组和对照组,每组50例,观察组给予复方阿嗪米特肠溶片100mg/次,3次/d;对照组给予健胃消食片处理,连续服用2周。观察比较两组患者的治疗前后症状积分情况及临床治疗有效率。结果：两组患者治疗前消化不良积分差异无统计学意义（P>0.05）;经过2周治疗后,观察组消化系统症状改善的总有效率明显高于对照组患者,观察组症状积分低于对照组,差异有统计学意义（P<0.05）。在治疗过程中各组均未出现严重的不良反应。结论：复方阿嗪米特肠溶片对功能性消化不良患者治疗效果显著,对缓解消化系统症状具有重要意义。     

Synthesis,Cytotoxicity and Antileishmanial Activity of Some N-(2-(indol-3-yl)ethyl)-7-chloroquinolin-4-amines

We report herein the condensation of 4,7-dichloroquinoline (1) with tryptamine (2) and D-tryptophan methyl ester (3) . Hydrolysis of the methyl ester adduct (5) yielded the free acid (6) . The compounds were evaluated in vitro for activity against four different species of Leishmania promastigote forms and for cytotoxic activity against Kb and Vero cells. Compound (5) showed good activity against the Leishmania species tested, while all three compounds displayed moderate activity in both Kb and Vero cells.     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

Lung disease and PKCs

The lung offers a rich opportunity for development of therapeutic strategies focused on isozymes of protein kinase C (PKCs). PKCs are important in many cellular responses in the lung, and existing therapies for pulmonary disorders are inadequate. The lung poses unique challenges as it interfaces with air and blood, contains a pulmonary and systemic circulation, and consists of many cell types. Key structures are bronchial and pulmonary vessels, branching airways, and distal air sacs defined by alveolar walls containing capillaries and interstitial space. The cellular composition of each vessel, airway, and alveolar wall is heterogeneous. Injurious environmental stimuli signal through PKCs and cause a variety of disorders. Edema formation and pulmonary hypertension (PHTN) result from derangements in endothelial, smooth muscle (SM), and/or adventitial fibroblast cell phenotype. Asthma, chronic obstructive pulmonary disease (COPD), and lung cancer are characterized by distinctive pathological changes in airway epithelial, SM, and mucous-generating cells. Acute and chronic pneumonitis and fibrosis occur in the alveolar space and interstitium with type 2 pneumocytes and interstitial fibroblasts/myofibroblasts playing a prominent role. At each site, inflammatory, immune, and vascular progenitor cells contribute to the injury and repair process. Many strategies have been used to investigate PKCs in lung injury. Isolated organ preparations and whole animal studies are powerful approaches especially when genetically engineered mice are used. More analysis of PKC isozymes in normal and diseased human lung tissue and cells is needed to complement this work. Since opposing or counter-regulatory effects of selected PKCs in the same cell or tissue have been found, it may be desirable to target more than one PKC isozyme and potentially in different directions. Because multiple signaling pathways contribute to the key cellular responses important in lung biology, therapeutic strategies targeting PKCs may be more effective if combined with inhibitors of other pathways for additive or synergistic effect. Mechanisms that regulate PKC activity, including phosphorylation and interaction with isozyme-specific binding proteins, are also potential therapeutic targets. Key isotypes of PKC involved in lung pathophysiology are summarized and current and evolving therapeutic approaches to target them are identified.     

In vitro studies on sterically stabilized liposomes (SL) as enzyme carriers in organophosphorus (OP) antagonism

This study describes a new approach for organophosphorous (OP) antidotal treatment by encapsulating an OP hydrolyzing enzyme, OPA anhydrolase (OPAA), within sterically stabilized liposomes. The recombinant OPAA enzyme was derived from Alteromonas strain JD6. It has broad substrate specificity to a wide range of OP compounds: DFP and the nerve agents, soman and sarin. Liposomes encapsulating OPAA (SL)* were made by mechanical dispersion method. Hydrolysis of DFP by (SL)* was measured by following an increase of fluoride ion concentration using a fluoride ion selective electrode. OPAA entrapped in the carrier liposomes rapidly hydrolyze DFP, with the rate of DFP hydrolysis directly proportional to the amount of (SL)* added to the solution. Liposomal carriers containing no enzyme did not hydrolyze DFP. The reaction was linear and the rate of hydrolysis was first order in the substrate. This enzyme carrier system serves as a biodegradable protective environment for the recombinant OP-metabolizing enzyme, OPAA, resulting in prolongation of enzymatic concentration in the body. These studies suggest that the protection of OP intoxication can be strikingly enhanced by adding OPAA encapsulated within (SL)* to pralidoxime and atropine.     

Gender-related symptoms and correlates of alcohol dependence among men and women with a lifetime diagnosis of alcohol use disorders

This study explored gender-related symptoms and correlates of alcohol dependence in a crosssectional study of 150 men and 150 women with a lifetime diagnosis of alcohol use disorders (AUD). Participants were recruited in equal numbers from treatment settings, correctional centres and the general community. Standardized measures were used to determine participants' use of substances, history of psychiatric disorders and psychosocial stress, their sensation seeking and family history of substance use and mental health disorders. Multivariate analyses were used to detect patterns of variables associated with gender and the lifetime severity of AUD. Men had a longer history of severe AUD than women. Women had similar levels of alcohol dependence and medical and psychological sequelae as men, despite 6 fewer years of AUD. More women than men had a history of severe psychosocial stress, severe dependence on other substances and antecedent mental health problems, especially mood and anxiety disorders. There were differences in family history of alcohol-related problems approximating same-gender aggregation. The severity of a lifetime AUD was predicted by its earlier age at onset and the occurrence of other disorders, especially anxiety, among both men and women. The limitations in the generalizability of these findings due to sample idiosyncrasies are discussed.     

Steroidal sapogenin contents in some domestic plants

In order to find out the values of the steroid resources for the future use. the compositions and contents of steroidal sapogenins from 13 domestic plants have been investigated. As a result,Dioscorea nipponica, D. quinqueloba andSmilax china were found to have large amount of diosgenin. And pennogenin inTrillium kamtschaticum andParis verticillata, yuccagenin inAllium fistulosum, hecogenin inAgave americana and neochlorogenin inSolanum nigum were appeared to be major steroidal sapogenins.